Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of tiratricol on other drugs

5 evidence topics · 2 sources

Oral anticoagulants

“EMCITATE may increase the response to oral anticoagulant therapy, which may increase the risk of hemorrhage. Therefore, a reduction in the dose of anticoagulant may be warranted if administered concomitantly with EMCITATE. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments of the anticoagulant.” (opens the prescribing information at this quote)

Psychostimulants

“Administration of psychostimulants (e.g., caffeine, norepinephrine–dopamine reuptake inhibitors (NDRIs), and amphetamines) in combination with high doses of EMCITATE may lead to increased heart rate and blood pressure. Concomitant use of psychostimulants and EMCITATE is not recommended.” (opens the prescribing information at this quote)

In vitro enzyme and transporter inhibition and induction

“CYP450 Enzymes: Tiratricol is unlikely to inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 at clinically relevant doses.” (opens the prescribing information at this quote)

“UGT Enzymes: Tiratricol is unlikely to inhibit UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 at clinically relevant doses.” (opens the prescribing information at this quote)

“Tiratricol is unlikely to inhibit BCRP, OAT1, OAT3, OATP1B1 transporters at clinically relevant doses.” (opens the prescribing information at this quote)

Effects of tiratricol on other drugs: European summary of product characteristics
Drug or drug classStatement in the summary of product characteristics
CYP3A4 substrates with narrow therapeutic indices“Based on in vitro data there is an indication that tiratricol may induce CYP3A4 at a gut level and therefore medicinal products with narrow therapeutic indices that are dependent on CYP3A4, including but not limited to: alfentanil, cisapride, cyclosporine, ergot derivatives, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, atorvastatin, lovastatin, and simvastatin should be used with caution.”
P-gp and BCRP substrates with narrow therapeutic indices“Medicinal products that are substrates of P-glycoprotein (P-gp) or Breast Cancer Resistance Protein (BCRP) efflux transporters with narrow therapeutic indices should also be used with caution.”
Anti-diabetic agents“Tiratricol may reduce blood glucose levels. The dose of anti-diabetic agents may need to be adjusted if administered concomitantly with tiratricol. Periodic monitoring of blood glucose is necessary (see section 4.4).”
Oral anticoagulants“The effect of anti-coagulant therapy may be increased during treatment with tiratricol. This may increase the risk of haemorrhage. The dose of anti-coagulant therapy may have to be adjusted if administered concomitantly with tiratricol.”
Drug-laboratory interference

“An LC-MS/MS method should be used for total T3 measurement due to interference of EMCITATE with T3 immunoassays.” (opens the prescribing information at this quote)